Evidence map›Paper›PMID 29155147›Full record

ArticleBiochemical pharmacology2018

Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.

Harshini Neelakantan, Virginia Vance, Michael D Wetzel, Hua-Yu Leo Wang, Stanton F McHardy, Celeste C Finnerty, Jonathan D Hommel, Stanley J Watowich

Open access · greenAbstract read
In one paragraph

Article in Biochemical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Review
  3. Efficacious Anti-Cancer Drugs Targeting NicotinamidePharmaceuticals (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. The role of NADnpj metabolic health and disease · 2025
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Inhibitors of NADInternational journal of molecular sciences · 2024
    Review
  16. Control of NADThe EMBO journal · 2024
    Article
  17. Article
  18. Review
  19. Review
  20. NADCells · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Harshini NeelakantanDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77550, USA.
Virginia VanceDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77550, USA.
Michael D WetzelDepartment of Surgery, University of Texas Medical Branch, Galveston, TX 77550 USA; Shriners Hospitals for Children-Galveston, Galveston, TX 77550, USA.
Hua-Yu Leo WangDepartment of Chemistry and Center for Innovative Drug Discovery, University of Texas at San Antonio, San Antonio, TX 78249, USA.
Stanton F McHardyDepartment of Chemistry and Center for Innovative Drug Discovery, University of Texas at San Antonio, San Antonio, TX 78249, USA.
Celeste C FinnertyDepartment of Surgery, University of Texas Medical Branch, Galveston, TX 77550 USA; Shriners Hospitals for Children-Galveston, Galveston, TX 77550, USA.
Jonathan D HommelDepartment of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77550, USA.
Stanley J WatowichDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77550, USA. Electronic address: watowich@xray.utmb.edu.
The University of Texas Medical Branch at Galveston · USThe University of Texas at San Antonio · USShriners Hospitals for Children - Galveston · US

Funding

UTMB OAIC Research Education Component (REC)P30AG024832 · NIA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI JAMES S. GOODWIN, MD, MELISSA M. MORROW · 2005 to 2026
$26.7M
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip FractureU44AG074107 · NIA · RIDGELINE THERAPEUTICS, LLC · PI NEELAKANTAN, HARSHINI · 2021 to 2024
$4.2M
Effects of Chronic Catecholamine Exposure on Post-burn ScarringR01GM112936 · NIGMS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI FINNERTY, CELESTE CAMPBELL · 2015 to 2019
$1.8M
NIA NIH HHS P30 AG024832NIA NIH HHS U44 AG074107NIGMS NIH HHS R01 GM112936
6 · The paper itself

Abstract

There is a critical need for new mechanism-of-action drugs that reduce the burden of obesity and associated chronic metabolic comorbidities. A potentially novel target to treat obesity and type 2 diabetes is nicotinamide-N-methyltransferase (NNMT), a cytosolic enzyme with newly identified roles in cellular metabolism and energy homeostasis. To validate NNMT as an anti-obesity drug target, we investigated the permeability, selectivity, mechanistic, and physiological properties of a series of small molecule NNMT inhibitors. Membrane permeability of NNMT inhibitors was characterized using parallel artificial membrane permeability and Caco-2 cell assays. Selectivity was tested against structurally-related methyltransferases and nicotinamide adenine dinucleotide (NAD

Indexed as

3T3 CellsAdipocytesAnimalsAnti-Obesity AgentsCaco-2 CellsCell MembraneCell Membrane PermeabilityDiet, High-FatDose-Response Relationship, DrugEnzyme InhibitorsHumansMaleMiceMice, Inbred C57BLNicotinamide N-MethyltransferaseObesityAnti-Obesity AgentsEnzyme InhibitorsNicotinamide N-MethyltransferaseInhibitorsNicotinamide N-methyltransferaseObesityTherapeuticsWeight loss

Identifiers

PMID29155147
PMCPMC5826726
OpenAlexW2768796801

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.